Certara (NASDAQ:CERT) Given New $12.00 Price Target at Morgan Stanley

Certara (NASDAQ:CERT) had its price target dropped by Morgan Stanley from $16.00 to $12.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 32.23% from the stock’s previous close.

A number of other research analysts have also recently issued reports on CERT. Stephens lowered their price objective on Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, December 12th. Zacks Research upgraded shares of Certara from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Rothschild Redb upgraded shares of Certara to a “strong-buy” rating in a research note on Friday, November 21st. Rothschild & Co Redburn started coverage on shares of Certara in a research note on Friday, November 21st. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Craig Hallum assumed coverage on shares of Certara in a research report on Monday, September 29th. They set a “buy” rating and a $16.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $12.91.

Certara Stock Up 2.4%

NASDAQ CERT traded up $0.22 during trading hours on Thursday, reaching $9.08. 902,419 shares of the company’s stock traded hands, compared to its average volume of 1,824,872. Certara has a 52-week low of $8.02 and a 52-week high of $15.69. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The firm has a 50-day simple moving average of $10.17 and a 200 day simple moving average of $10.81. The firm has a market cap of $1.45 billion, a PE ratio of 129.64 and a beta of 1.46.

Certara (NASDAQ:CERT) last announced its earnings results on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. Certara had a net margin of 2.62% and a return on equity of 5.18%. The business had revenue of $104.62 million during the quarter, compared to the consensus estimate of $104.53 million. During the same quarter last year, the firm earned $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. Sell-side analysts anticipate that Certara will post 0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Certara

A number of institutional investors and hedge funds have recently modified their holdings of the company. Associated Banc Corp grew its holdings in shares of Certara by 9.7% in the third quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock worth $146,000 after acquiring an additional 1,051 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its position in Certara by 2.5% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 45,745 shares of the company’s stock worth $535,000 after purchasing an additional 1,136 shares during the last quarter. Versant Capital Management Inc grew its stake in shares of Certara by 66.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after purchasing an additional 1,153 shares during the period. Osaic Holdings Inc. increased its position in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd lifted its stake in shares of Certara by 22.5% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 6,665 shares of the company’s stock worth $78,000 after purchasing an additional 1,223 shares during the period. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.